The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association
- PMID: 28257716
- DOI: 10.1053/j.gastro.2017.01.031
The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association
Abstract
Background & aims: The purpose of this review is to evaluate the risks associated with long-term use of proton pump inhibitors (PPIs), focusing on long-term use of PPIs for three common indications: gastroesophageal reflux disease (GERD), Barrett's esophagus (BE), and non-steroidal anti-inflammatory drug (NSAID) bleeding prophylaxis.
Methods: The recommendations outlined in this review are based on expert opinion and on relevant publications from PubMed, EMbase, and the Cochrane library (through July 2016). To identify relevant ongoing trials, we queried clinicaltrials.gov. To assess the quality of evidence, we used a modified approach based on the GRADE Working Group. The Clinical Practice Updates Committee of the American Gastroenterological Association has reviewed these recommendations. Best Practice Advice 1: Patients with GERD and acid-related complications (ie, erosive esophagitis or peptic stricture) should take a PPI for short-term healing, maintenance of healing, and long-term symptom control. Best Practice Advice 2: Patients with uncomplicated GERD who respond to short-term PPIs should subsequently attempt to stop or reduce them. Patients who cannot reduce PPIs should consider ambulatory esophageal pH/impedance monitoring before committing to lifelong PPIs to help distinguish GERD from a functional syndrome. The best candidates for this strategy may be patients with predominantly atypical symptoms or those who lack an obvious predisposition to GERD (eg, central obesity, large hiatal hernia). Best Practice Advice 3: Patients with Barrett's esophagus and symptomatic GERD should take a long-term PPI. Best Practice Advice 4: Asymptomatic patients with Barrett's esophagus should consider a long-term PPI. Best Practice Advice 5: Patients at high risk for ulcer-related bleeding from NSAIDs should take a PPI if they continue to take NSAIDs. Best Practice Advice 6: The dose of long-term PPIs should be periodically reevaluated so that the lowest effective PPI dose can be prescribed to manage the condition. Best Practice Advice 7: Long-term PPI users should not routinely use probiotics to prevent infection. Best Practice Advice 8: Long-term PPI users should not routinely raise their intake of calcium, vitamin B12, or magnesium beyond the Recommended Dietary Allowance (RDA). Best Practice Advice 9: Long-term PPI users should not routinely screen or monitor bone mineral density, serum creatinine, magnesium, or vitamin B12. Best Practice Advice 10: Specific PPI formulations should not be selected based on potential risks.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.Gastroenterology. 2022 Apr;162(4):1334-1342. doi: 10.1053/j.gastro.2021.12.247. Epub 2022 Feb 17. Gastroenterology. 2022. PMID: 35183361 Review.
-
AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review.Clin Gastroenterol Hepatol. 2022 May;20(5):984-994.e1. doi: 10.1016/j.cgh.2022.01.025. Epub 2022 Feb 2. Clin Gastroenterol Hepatol. 2022. PMID: 35123084 Free PMC article. Review.
-
AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review.Gastroenterology. 2024 Nov;167(6):1228-1238. doi: 10.1053/j.gastro.2024.06.038. Epub 2024 Sep 11. Gastroenterology. 2024. PMID: 39269391 Review.
-
AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review.Clin Gastroenterol Hepatol. 2023 Jun;21(6):1414-1421.e3. doi: 10.1016/j.cgh.2023.01.040. Epub 2023 Apr 14. Clin Gastroenterol Hepatol. 2023. PMID: 37061897
-
Extraesophageal Symptoms and Diseases Attributed to GERD: Where is the Pendulum Swinging Now?Clin Gastroenterol Hepatol. 2018 Jul;16(7):1018-1029. doi: 10.1016/j.cgh.2018.02.001. Epub 2018 Feb 7. Clin Gastroenterol Hepatol. 2018. PMID: 29427733 Review.
Cited by
-
Helicobacter pylori, esophageal precancerous lesions, and proton pump inhibitor overuse.World J Gastroenterol. 2024 Nov 14;30(42):4591-4596. doi: 10.3748/wjg.v30.i42.4591. World J Gastroenterol. 2024. PMID: 39563751 Free PMC article. Review.
-
Association between proton pump inhibitors and dementia risk: a Mendelian randomization study.Sci Rep. 2024 Nov 19;14(1):28624. doi: 10.1038/s41598-024-79821-1. Sci Rep. 2024. PMID: 39562663 Free PMC article.
-
Proton pump inhibitors in inpatients: Are we getting it right? A retrospective analysis.Qatar Med J. 2024 Nov 11;2024(4):60. doi: 10.5339/qmj.2024.60. eCollection 2024. Qatar Med J. 2024. PMID: 39552948 Free PMC article.
-
Proton-Pump Inhibitors and Fat Absorption in Cystic Fibrosis and Pancreatic Insufficiency: A Randomized Crossover Pilot Trial.Dig Dis Sci. 2024 Nov 13. doi: 10.1007/s10620-024-08728-8. Online ahead of print. Dig Dis Sci. 2024. PMID: 39537890
-
Knowledge and Attitudes Regarding the Inappropriate Use of Proton Pump Inhibitors Among Students of Umm Al-Qura University in Saudi Arabia: A Cross-Sectional Study.Cureus. 2024 Oct 11;16(10):e71282. doi: 10.7759/cureus.71282. eCollection 2024 Oct. Cureus. 2024. PMID: 39534847 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
